zipalertinib
·Code: CLN-081, TAS6417
zipalertinib: developed by 1 company.
zipalertinib evidence translation
What we can confirm
No verified FDA or trial count is available.
What it means
Source-backed records connect zipalertinib to CGEM; that link alone does not prove the drug works.
What to watch
Evidence is limited; missing information remains unknown.
BioSniper AIPage evidence connected
Prepared research question
How could zipalertinib → CGEM affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
EGFR exon 20 (EGFRex20) insertion non-small-cell lung cancer (NSCLC); being evaluated in patients who progressed after prior systemic therapy and in previously untreated advanced EGFRex20 NSCLC (first-line in combination with chemotherapy); also evaluated in cohorts including treatment-naïve, prior treated, and patients with active brain metastasesLocally advanced or metastatic EGFR ex20ins NSCLC
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Cullinan Therapeutics, Inc. (CGEM) EGFR exon 20 (EGFRex20) insertion non-small-cell lung cancer… | Phase 3 |
| Cullinan Therapeutics, Inc. (CGEM) Locally advanced or metastatic EGFR ex20ins NSCLC | Phase 3 |